BACKGROUND: Cancer and its treatments frequently compromise skin integrity, leading to xerosis, pruritus, dermatitis, radiation-induced skin damage, and secondary infections. These cutaneous adverse events (cAEs) are not merely superficial; they profoundly impact patient quality of life (QoL), contributing to physical discomfort, psychosocial distress, and poorer treatment adherence. Even mild skin toxicities elevate dermatology-specific QoL measures, affecting mood and social function. Additionally, new targeted therapies, such as daraxonrasib-a KRAS inhibitor under development for pancreatic cancer-can cause a dose-limiting acneiform facial rash. METHODS: In this study, relevant literature on skin care in cancer patients was identified using PubMed. Evidence from clinical studies, reviews, and expert guidelines was summarized. RESULTS: Evidence supports proactive skincare with gentle pH-balanced cleansers, ceramide- or urea-based moisturizers, and broad-spectrum photoprotection to lessen symptom severity and improve QoL. Sun protection remains essential because chemotherapy and immunomodulatory therapies increase photosensitivity, accelerate photoaging, and raise the risk of secondary skin cancers. Supportive skincare interventions have also shown emotional and functional benefits, including improved mood and self-image during chemotherapy and radiation treatment. CONCLUSION: Despite strong data supporting moisturization, barrier repair, and photoprotection, oncologic treatment plans often overlook these interventions. By integrating dermatologic education and skincare maintenance into standard oncologic practice, we can minimize cAEs, foster treatment compliance, and enhance patients' physical comfort and psychosocial well-being. This narrative review synthesizes mechanistic insights, clinical evidence, and practical recommendations for oncologists to champion comprehensive skincare in all cancer patients, whether directly affected by skin issues or not.
Kaminsky et al. (Sat,) studied this question.